Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660725 · ClinicalTrials.gov registry record · Phase 1
Study of GemOx and Vandetanib in Advanced Solid Malignancy
A Phase 1 study of Advanced Incurable Solid Malignancy, sponsored by Leonard Appleman.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00660725 is a Phase 1 study of Advanced Incurable Solid Malignancy that has completed, run by Leonard Appleman. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00660725, a Phase 1 study of Advanced Incurable Solid Malignancy, has completed, sponsored by Leonard Appleman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Vandetanib
Study Locations (1)
Pennsylvania
- University of Pittsburgh Cancer Institute / Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660725
The ClinicalTrials.gov registry entry for NCT00660725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leonard Appleman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Incurable Solid Malignancy appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT00660725 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00660725 about?
NCT00660725 is a clinical study titled "Study of GemOx and Vandetanib in Advanced Solid Malignancy". This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.
What is the current status of trial NCT00660725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-02. Estimated completion is 2010-12.
What conditions does trial NCT00660725 study?
This clinical trial studies the following conditions: Advanced Incurable Solid Malignancy.
What interventions are being tested in trial NCT00660725?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00660725?
This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660725 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.